Effect of casein and protamine on the enzymatic degradation and the orally hypoglycemic action of insulin

Yaoxue Xuebao

Volumn 39, Issue 10, 2004, Pages 844-848

  Qi, Rong ^a   Ping, Qi Neng ^a   Xu, Rui Yang ^a   Shi, Yong Ping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

chymotrypsin; Casein; Enteric microsphere; Insulin; Protamine; Sodium N 8 (2 hydroxybenzoyl)amino caprylate; Trypsin

Indexed keywords

CASEIN; CHYMOTRYPSIN A; INSULIN; MICROSPHERE; ORAL ANTIDIABETIC AGENT; PROTAMINE; PROTECTIVE AGENT; SODIUM N [8 (2 HYDROXYBENZOYL)AMINO]CAPRYLATE; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; ENZYMATIC DEGRADATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOGLYCEMIA; INTESTINE FLUID; NONHUMAN; PROTECTION; RAT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CAPRYLATES; CASEINS; CHYMOTRYPSIN; DRUG DELIVERY SYSTEMS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICROSPHERES; PROTAMINES; RATS; RATS, SPRAGUE-DAWLEY; SOLUTIONS; TRYPSIN;

EID: 12344267229     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Nagareya N, Uchida T, Matsuyama K. Preparation and characterization of enteric microspheres containing bovine insulin by a W/O/W emulsion solvent evaporation method [J]. Chem Pharm Bull, 1993,46(10):1613-1617.
2. Aunget BJ. Intestinal permeation enhancers [J]. J Pharm Sci, 2000,89(4):429-442.
3. Kennedy FT. Recent developments in insulin delivery techniques: current status and future potential [J]. Drugs, 1991,42(2):213-227.
4. Playford RJ, Woodman AC, Clark P, et al. Effect of luminal growth factor preservation on intestinal growth [J]. Lancet, 1993,341(8849):843-848.
5. Playford RJ, Marchbank T, Calnan DP, et al. Epidermal growth factor is digested to smaller, less active forms in acid gastric juice [J]. Gastroenterology, 1995,108(1): 92-101.
6. Amorim MJ, Ferreira JP. Microparticles for delivering therapeutic peptides and proteins to the lumen of the small intestine [J]. Eur J Pharm Biopharm, 2001,52(1): 39-44.
7. Leone-Bay A, Paton DR, Variano B, et al. Acylated non-α-amino acids as novel agents for the oral delivery of heparin sodium, USP [J]. J Controlled Release, 1998, 50(1-3):41-49.
8. Mlynek GM, Calvo LJ, Robinson JR. Carrier-enhanced human growth hormone absorption across isolated rabbit intestinal tissue [J]. Int J Pharm, 2000,179(1-2): 13-21.
9. Wu SJ, Robinson JR. Transport of human growth hormone across Caco-2 cells with novel delivery agents: evidence for P-glycoprotein involvement [J]. J Controlled Release, 1999,62(1-2):171-177.
10. Qi R, Ping QN, Zhao W. Studied on gastrointestinal absorption enhancement effect and mechanism of SNAC to insulin solution [J]. Acta Pharm Sin, 2003,38(12):953-956.
11. Qi R, Ping QN. Study on gastrointestinal absorption enhancement of insulin by administrating enteric microspheres and SNAC to rats [J]. J Microencapsul, 2004,21(1):37-45.
12. Schilling RJ, Mitra AK. Degradation of insulin by trypsin and alpha-chymotrypsin [J]. Pharm Res, 1991,8(6): 721-727.